# Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism

> **NCT04246073** · — · UNKNOWN · sponsor: **Hellenic Society of Surgical Oncology** · enrollment: 400 (estimated)

## Conditions studied

- Cancer
- Cancer Diagnosis
- Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04246073
- **Lead sponsor:** Hellenic Society of Surgical Oncology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04246073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04246073, "Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04246073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*